UNASSIGNED: Relapse of @entity521 ( @entity521 ) is deemed invariably fatal yet increasing numbers of @entity521 @entity1 achieve a second complete/very good partial remission (CR/VGPR), hence the urgency to find a successful consolidative therapy. Identifying efficacy in @entity1 without assessable disease, however, is problematic. We report the first study providing outcome data for this group of @entity1 with poor prognosis. To prevent another relapse, @entity521 @entity1 in second or later CR/VGPR received the anti-GD2 murine antibody 3F8 plus @entity2841 plus @entity10211 in a Phase II trial. Upon meeting the target aim for progression-free survival (PFS) in the initial cohort of 33 @entity1 , the trial was amended to allow @entity1 who developed human anti-mouse antibody (HAMA) to receive rituximab to ablate HAMA with or without low-dose maintenance chemotherapy until immunotherapy could resume. For the total of 101 study @entity1 , 5-year PFS and @entity1349 ( @entity1349 ) rates were 33%    5% and 48%    5%, respectively. Among the 33 long-term progression-free survivors, 19 had @entity4180 amplification, 19 had previously received anti-GD2 immunotherapy plus @entity10211 (as first-line therapy), and 15 never received maintenance chemotherapy. In a multivariate analysis of prognostic factors, only absence of minimal @entity66 in bone marrow after 2 cycles of immunotherapy and before initiation of @entity10211 or anti-HAMA therapy was significantly favorable for both PFS and @entity1349 . Therefore, long-term PFS is possible for @entity521 @entity1 who achieve at least a second CR/VGPR and receive consolidation that includes anti-GD2 immunotherapy plus @entity10211 , even if the @entity1 received these biological treatments before relapse. Results from this prospective study will aid in the development of future Phase II studies for this growing ultra high-risk @entity1 population.

Prolonged progression-free survival after consolidating second or later remissions of @entity521 with Anti-GD2 immunotherapy and XXXX : a prospective Phase II study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity10211 :: ('MESH:D015474', 'Chemical') :: ['isotretinoin'] @entity521 :: ('MESH:D009447', 'Disease') :: ['HR-NB', 'high-risk neuroblastoma'] @entity4180 :: ('4613', 'Gene') :: ['MYCN'] @entity2841 :: ('1437', 'Gene') :: ['granulocyte-macrophage colony-stimulating factor'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity10211 :: (MESH:D015474,Chemical) :: ['isotretinoin']
